OBJECTIVES: To describe first-dose and steady state pharmacokinetics (PKs) of dolutegravir (DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal fluid (RF) of healthy HIV-negative men. DESIGN: A phase 1, open-label, PK study that enrolled 12 healthy men taking 50 mg DTG daily for 8 days. METHODS: Eleven paired BP samples and 3 SF and RF samples were collected over 24 hours after first (PK1) and multiple (PK2) dosing. RT biopsies were collected at 1 of 6 time points at PK1 and PK2 to generate composite PK profiles. DTG concentrations were analyzed by validated liquid chromatography-tandem mass spectrometry (LC-MS/MS). Noncompartmental PK analysis was conducted with Phoenix WinNonlin v6.3, and Spearman rank correlations were determined using SAS v9.3. RESULTS: BP area under the concentration-time curves (AUCs) were similar to previous reports, and concentrations at 24 hours (C24 h) were 6- to 34-fold greater than the protein-adjusted concentration required for 90% viral inhibition (PA-IC90) of 64 ng/mL. SF exposures were <7% of BP and below the PA-IC90. RT exposures were 17% of BP and ∼2-fold greater than the PA-IC90. RF AUCs were ∼2%-5% of RT and did not correlate with RT (rho = 0.43, P = 0.17). Accumulation of DTG with multiple dosing was observed in BP, SF, and RT. CONCLUSIONS: DTG BP PKs were consistent with previously published values. SF concentrations were <7% BP, with SF C24 h below the PA-IC90. However, SF protein binding was not measured. Although the AUC of DTG in RT was <20% BP, RT C24 h remained ∼2-fold higher than the PA-IC90. RF was not a strong surrogate for RT concentrations.
OBJECTIVES: To describe first-dose and steady state pharmacokinetics (PKs) of dolutegravir (DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal fluid (RF) of healthy HIV-negative men. DESIGN: A phase 1, open-label, PK study that enrolled 12 healthy men taking 50 mg DTG daily for 8 days. METHODS: Eleven paired BP samples and 3 SF and RF samples were collected over 24 hours after first (PK1) and multiple (PK2) dosing. RT biopsies were collected at 1 of 6 time points at PK1 and PK2 to generate composite PK profiles. DTG concentrations were analyzed by validated liquid chromatography-tandem mass spectrometry (LC-MS/MS). Noncompartmental PK analysis was conducted with Phoenix WinNonlin v6.3, and Spearman rank correlations were determined using SAS v9.3. RESULTS: BP area under the concentration-time curves (AUCs) were similar to previous reports, and concentrations at 24 hours (C24 h) were 6- to 34-fold greater than the protein-adjusted concentration required for 90% viral inhibition (PA-IC90) of 64 ng/mL. SF exposures were <7% of BP and below the PA-IC90. RT exposures were 17% of BP and ∼2-fold greater than the PA-IC90. RF AUCs were ∼2%-5% of RT and did not correlate with RT (rho = 0.43, P = 0.17). Accumulation of DTG with multiple dosing was observed in BP, SF, and RT. CONCLUSIONS:DTG BP PKs were consistent with previously published values. SF concentrations were <7% BP, with SF C24 h below the PA-IC90. However, SF protein binding was not measured. Although the AUC of DTG in RT was <20% BP, RT C24 h remained ∼2-fold higher than the PA-IC90. RF was not a strong surrogate for RT concentrations.
Authors: T M Lampinen; C W Critchlow; J M Kuypers; C S Hurt; P J Nelson; S E Hawes; R W Coombs; K K Holmes; N B Kiviat Journal: AIDS Date: 2000-03-31 Impact factor: 4.177
Authors: P L Vernazza; L Troiani; M J Flepp; R W Cone; J Schock; F Roth; K Boggian; M S Cohen; S A Fiscus; J J Eron Journal: AIDS Date: 2000-01-28 Impact factor: 4.177
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Sherene Min; Louis Sloan; Edwin DeJesus; Trevor Hawkins; Lewis McCurdy; Ivy Song; Richard Stroder; Shuguang Chen; Mark Underwood; Tamio Fujiwara; Stephen Piscitelli; Jay Lalezari Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Kevin C Brown; Kristine B Patterson; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Julie B Dumond; Melissa B Spacek; Paris E Heidt; Myron S Cohen; Angela D M Kashuba Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: Richard A Zuckerman; William L H Whittington; Connie L Celum; Tarquin K Collis; Aldo J Lucchetti; Jorge L Sanchez; James P Hughes; Jose L Sanchez; Robert W Coombs Journal: J Infect Dis Date: 2004-06-09 Impact factor: 5.226
Authors: Stephen A Greene; Jingxian Chen; Heather M A Prince; Craig Sykes; Amanda P Schauer; Kimberly Blake; Julie A E Nelson; Cynthia L Gay; Myron S Cohen; Julie B Dumond Journal: Clin Pharmacol Ther Date: 2019-05-31 Impact factor: 6.875
Authors: Cecile D Lahiri; Nakita L Brown; Kevin J Ryan; Edward P Acosta; Anandi N Sheth; Cyra C Mehta; Jessica Ingersoll; Ighovwerha Ofotokun Journal: AIDS Date: 2018-09-24 Impact factor: 4.177